Pembrolizumab (Keytruda) in combination with Lenvatinib (Lenvima®) for the treatment of advanced or recurrent endometrial carcinoma (EC). Update February 2022

Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Lenvima®) for the treatment of advanced or recurrent endometrial carcinoma (EC). Update February 2022. Oncology Fact Sheet Nr. 68.

[thumbnail of Oncology Fact Sheet Nr.68_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
922kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 440-468 Uterine diseases
Language:	English
Series Name:	Oncology Fact Sheet Nr. 68
Deposited on:	12 Nov 2021 15:57
Last Modified:	09 Feb 2022 18:29

Repository Staff Only: item control page